Venus Remedies Ltd Hits New 52-Week High at Rs.872.8

Stock Performance and Market Context

On 2 Feb 2026, Venus Remedies Ltd (Stock ID: 568580), a key player in the Pharmaceuticals & Biotechnology sector, recorded an intraday high of Rs.872.8, representing a 4.97% gain from its opening price. Despite closing the day with a slight decline of 1.38%, the stock’s achievement of this new peak underscores its sustained upward trajectory over the past year.

The stock demonstrated notable volatility throughout the trading session, with an intraday price range spanning from a low of Rs.801 to the high of Rs.872.8, resulting in a weighted average price volatility of 5.69%. This price action reflects active trading interest and dynamic market conditions surrounding the stock.

Venus Remedies Ltd’s current price comfortably exceeds its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong bullish trend across multiple timeframes. This technical strength is particularly significant given the broader market backdrop, where the Sensex opened lower by 167.26 points but recovered sharply to close 0.39% higher at 81,041.15.

Long-Term Growth and Relative Performance

Over the past 12 months, Venus Remedies Ltd has delivered an exceptional return of 175.54%, vastly outperforming the Sensex’s modest 4.56% gain during the same period. The stock’s 52-week low was Rs.277.85, highlighting the substantial appreciation in value over the year.

This outperformance extends beyond the one-year horizon, with Venus Remedies Ltd also surpassing the BSE500 index in returns over the last three years, one year, and three months. Such consistent market-beating performance reflects the company’s strong fundamentals and investor confidence in its business model.

Financial Metrics Driving the Rally

Venus Remedies Ltd’s recent rally is underpinned by a series of strong financial results and operational metrics. The company reported a 96.37% growth in operating profit in its December 2025 quarter, marking a very positive earnings announcement. This follows a consistent pattern of positive results over the last five consecutive quarters, signalling sustained profitability improvements.

Key performance indicators further highlight the company’s operational efficiency. The Return on Capital Employed (ROCE) for the half-year period stands at a robust 13.99%, while the inventory turnover ratio is an impressive 6.58 times, indicating effective management of stock levels and working capital.

Quarterly PBDIT reached a high of Rs.37.52 crores, reinforcing the company’s strong earnings capacity. Additionally, Venus Remedies Ltd maintains a low average debt-to-equity ratio of zero, reflecting a conservative capital structure that reduces financial risk.

Valuation and Institutional Participation

The company’s valuation metrics suggest a fair pricing relative to its earnings and book value. With a Return on Equity (ROE) of 10.5% and a Price to Book Value ratio of 1.9, Venus Remedies Ltd trades at a premium compared to its peers’ historical averages. This premium is supported by the company’s strong profit growth of 182.3% over the past year, which outpaces its share price appreciation, resulting in a favourable PEG ratio of 0.1.

Institutional investors have increased their holdings by 0.67% in the previous quarter, now collectively owning 3.28% of the company’s shares. This growing institutional participation reflects confidence in the company’s fundamentals and long-term prospects.

Sector and Market Position

Operating within the Pharmaceuticals & Biotechnology sector, Venus Remedies Ltd benefits from a growing industry environment. The company’s market capitalisation grade is rated 4, indicating a solid mid-tier market cap status within its sector. Its Mojo Score currently stands at 74.0, with a Mojo Grade of Buy, reflecting a positive assessment of its overall quality and momentum. This is a slight adjustment from its previous Strong Buy grade, updated on 1 Feb 2026.

Despite the stock’s recent underperformance relative to its sector by 3.47% on the day it hit its new high, the broader sector and market trends remain supportive. The Sensex’s recovery and gains led by mega-cap stocks provide a favourable backdrop for mid-cap and small-cap stocks like Venus Remedies Ltd to continue their upward momentum.

Growth Considerations

While the company has demonstrated strong profit growth and operational efficiency, its net sales have grown at a more modest annual rate of 6.29% over the last five years. This slower top-line growth contrasts with the rapid expansion in profitability, suggesting a focus on margin improvement and cost management as key drivers of value creation.

Overall, Venus Remedies Ltd’s achievement of a new 52-week high at Rs.872.8 is a testament to its strong financial health, effective management, and positive market sentiment. The stock’s performance over the past year and its technical indicators highlight a sustained momentum that has propelled it to this significant milestone.

Unlock special upgrade rates for a limited period. Start Saving Now →